[This page is being regularly updated based on input from EFPIA members]
The research-based pharmaceutical industry in Europe stands in solidarity with the people of Ukraine. We condemn the invasion of their country and express our sorrow at the suffering it has caused. As an industry dedicated to saving and improving lives, we stand for peace.
Our first priority is to ensure that medicines reach the patients that need them in Ukraine, in the neighbouring EU Member States, in Russia and in other countries where access to medicines may be negatively impacted. We call on all parties to facilitate the safe passage of medicines and vaccines to those in need.
As a health-based industry and part of the wider EU healthcare community, we will work together to address the health needs of all those affected by this war, in Ukraine and in neighbouring countries as part of the wider humanitarian relief effort.
Our Member Companies and Associations are offering humanitarian support both in Ukraine and for the emerging refugee crisis in neighbouring EU Member States. To date this includes over 29 million packs of medicines and €300 million in overall support.
Find out more about our projects to support Ukraine
AbbVie's response to the Ukraine crisis
Our thoughts are with the people of Ukraine and those affected across the region. As a global biopharmaceutical company, we have a responsibility to patients who depend on our medicines. We are committed to ensuring our patients in Ukraine, Russia and throughout the region continue to have access to our essential and life-saving medicines.
AbbVie's presence in Ukraine and throughout the region
Our priority is to ensure the safety of our colleagues and help patients get the medicines they need.
As the tragic events continue to unfold in Ukraine, AbbVie has temporarily suspended operations for all our aesthetics products in Russia.
We do not have any manufacturing plants in the region. Importantly, we continue to monitor the safety of our employees in Ukraine and the surrounding region.
Status of Clinical Trials
AbbVie is doing everything possible to minimize disruption to the treatment and care of our patients and clinical trial participants. We have paused the start of new clinical studies and the screening and enrollment of clinical trial participants in ongoing studies in Ukraine and Russia. We are committed to ensuring our clinical trial participants have access to the investigational medicines they need.
Humanitarian / Philanthropic response
Our philanthropic focus is on humanitarian, employee, and donation support.
- Donating a total of $1 million to nonprofit partners for medical care and supplies for Ukraine and Ukrainian refugees.
- Donating essential medicines to the Ukrainian government and our disaster relief partners.
- Providing relief and additional financial support as needed to Ukrainian employees and their immediate families.
- Doubling the AbbVie Foundation's employee donation match for select disaster relief partners with active humanitarian relief efforts in Ukraine and surrounding countries.
As this situation evolves, we will continue working with our nonprofit partners and employees to support relief efforts as we hope for a peaceful resolution.
Contributing to humanitarian relief efforts
We continue to provide urgent humanitarian support in Ukraine and neighbouring countries. To date, we have committed over $10 million to response efforts, including donations of:
- Twenty-four pallets of medicines, worth $3 million, to our humanitarian relief partner Direct Relief, which is working directly with the Ukrainian Ministry of Health.
- $2 million to support relief agencies working in Ukraine, Poland and surrounding areas with a focus on providing healthcare and humanitarian assistance to those affected by the conflict. Funding is being provided to Project HOPE, working with and through the World Health Organization, and International Medical Corps.
- Medicines via The Red Cross affiliates in neighbouring countries to respond to the unfolding refugee crisis.
- >$1 million to UNICEF and The Red Cross, including over $500k of employee donations, which AstraZeneca is matching.
Supply of medicines
Patients rely on our essential and life-saving medicines, and it is more urgent than ever that medical supply chains continue to operate, enabling health systems and workers to deliver essential care. To this end, we are:
- Taking all required measures to ensure an uninterrupted supply of our essential and life-saving medicines to all patients in need.
- Supporting ongoing treatment at settlement sites and working with the governments to address the influx of patients in surrounding countries. This includes working with the EU on the continued provision of care for any Ukrainian refugees now residing in member states.
- Working together with the wider healthcare community, to ensure sanctions do not impact the supply of medicines to patients in need.
As far as clinical trials in Russia are concerned, we are not starting any new trials at this time and have paused enrolment of new patients into existing studies.
We are not planning any new investments in Russia.
Protecting the safety and wellbeing of our employees
We have 200 people in our Ukraine team and are providing all practical support possible to ensure their wellbeing, physical and financial security. This includes:
- Providing additional financial support.
- Setting up advice and emotional support services for employees and their families.
- Rolling out virtual online sessions for employees’ children to maintain educational activities.
- Helping those now in neighbouring countries, such as providing temporary accommodation for our team members and their families.
We continue to be deeply concerned by the tragic war in Ukraine, the devastating losses of civilians and the suffering of the entire Ukrainian population.
This led us to take several further and immediate actions:
In addition to the original donation of BERLIN-CHEMIE, a further donation of 200,000 euros directly to the Red Cross was carried out at Menarini Group level, complemented by 60,000 euros donated worldwide by its employees (matched equally by the Group), totalling the economic donations at 420,000 euros. Including the continuous medicine donations, our total contribution dedicated to the Ukrainian people is well over 1 million euros by now.
In Russia, we have stopped all advertising spending, ceased all new investments and implemented a headcount freeze. International sanctions exclude pharmaceuticals and we continue to supply medicines to Russia focused on patients who depend upon them.
We stand with the Ukrainian people and hope for a peaceful resolution as soon as possible.
Boehringer Ingelheim condemns the military aggression against Ukraine.
“On behalf of the Board of Managing Directors, I would like to express our feelings of sorrow and consternation over the start of a war in the middle of Europe. This affects people across the region, where families have members on both sides of the border, and where sons and daughters are called to duty in a war that only brings suffering and pain”, says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “War can never be accepted as the means of resolving conflicts.”
It was in February 1992 that we established our presence in Ukraine and Russia, which has grown to a total of nearly 800 employees today. "During these 30 years, we have achieved many milestones together in the interest of health, for the benefit of patients, and in the interest of life. Our Ukrainian as well as Russian colleagues have become integral members of the Boehringer Ingelheim family,” Hubertus von Baumbach continued. "Our thoughts are with them, as well as the many people who simply want to live in peace. On behalf of my colleagues, my deepest sympathies are with them all.”
“We have decided to make a donation of EUR 2.5 million* to charitable organizations providing humanitarian support to Ukraine and its citizens.”
Many colleagues are working to ensure the safety and well-being of our employees and their families in any way possible. We are in close contact with our Ukrainian colleagues. At the same time, we are seeking to limit the impact of the conflict on the supply of medicines to patients for humanitarian reasons across both countries. “We would like to thank all who have worked tirelessly during the past days to provide help wherever help can be provided.” Hubertus von Baumbach promises: “We will do everything to help our impacted colleagues, their families and communities.”
We realize that the war will have a long-term impact. We will therefore donate 12 monthly payments of each EUR 1 million to the Polish and German Red Cross organizations, from this month (March).
The war in Ukraine continues and it is clear that much help is still needed in many areas. In March 2022 we pledged our support for Ukraine via making financial donations to several charitable organizations and via donating our medical products. Reflecting on the year 2022, we have committed over EUR 25 million in financial support and medicines. Our monthly donations to the Red Cross will continue into the new year.
* The donation will be distributed to the following charitable organizations:
- EUR 750k to International Committee of the Red Cross (via German Red Cross - DRK)
- EUR 750k to Aktionsbündnis Katastrophenhilfe
- EUR 500k to Aktion Deutschland Hilft
- EUR 500k to UNO-Flüchtlingshilfe
Read more here
Like many around the world, the people at Chiesi are shocked by the ongoing conflict as we witness the distress of all those affected. Chiesi strongly condemns all acts of violence, and we call for a peaceful and immediate resolution of the ongoing conflict in Ukraine.
In more than 85 years of our history, we have always honoured our mission to improve the quality of life of our patients, and this is what continues to guide us in these turbulent times and leads us to focus on concrete actions that can bring help directly to people in need and support all our patients and colleagues.
Chiesi Group plans to maintain operations in the Russian territories, focusing primarily on medical information and disease awareness and ensure access to our therapeutic options.
Chiesi Group is however temporarily pausing any new recruitment of patients for all ongoing clinical trials in Russia, though continuing to treat all those already enrolled and ensuring they receive all the therapeutic solutions they need. Terminating all our activities would only deprive people of the medicines they need, add further suffering, and contradict our purpose. Our focus will always remain on our patients, and Chiesi will continue to prioritise uninterrupted access to treatments to patients in Ukraine and Russia and surrounding territories, despite the unstable situation.
Our people are, and always have been, at the heart of our actions and decisions and in these complex times, where situations change rapidly, we will continue to support our colleagues wherever they are to ensure, as best as we can, their safety and wellbeing.
Support to the Ukrainian Community
Chiesi Group has allocated an initial sum of 1.5 million-euro, part of which has already been committed to support international humanitarian NGOs, such as UNHCR - the UN Refugee Agency, the Red Cross and UNICEF, and international NGOs with a long-lasting and solid presence in Ukraine, working for specific target of beneficiaries, such as oncological children as well as initiatives for the reception of refugees in hosting countries. Moreover, Chiesi Group is matching employees’ donations for selected partners in support to local and international organizations. In addition to monetary support, Chiesi is constantly monitoring drug donation requests received from different channels worldwide and responding, whenever the requests can be met, by donating Chiesi drugs. Among others, Chiesi has donated life-saving treatments for neonates and transplant patients in Ukraine. Chiesi Group is also continuing to support International Health Partners (IHP), a selected partner since 2016, to aid its mission to help individuals and communities access the essential medicines and health supplies they need and strengthen health systems when they are put under strain by natural or man-made crises.
We continue to be deeply saddened by the conflict in Ukraine and horrified by the threat to peace, freedom, and security in Europe and beyond.
Our unwavering solidarity and thoughts are with the people of Ukraine as well as our colleagues, families and loved ones in the region.
In light of the growing shortage of pharmaceuticals and medical supplies, and based on the local needs of Ukrainian citizens, in June 2022, Daiichi Sankyo arranged to have medicines for infectious diseases sent to Ukraine.
With the cooperation of the United Nations Office for Project Services (UNOPS), Daiichi Sankyo’s medicines arrived in Ukraine in July 2022 and have subsequently been distributed to hospitals and other locations within the country by local NGOs.
We strongly hope that the medicines we provided will be of use to the people of Ukraine and its surrounding areas who have suffered greatly over the course of the conflict.
Our other activities in support of Ukraine are as follows.
To support humanitarian aid for those impacted by the conflict, Daiichi Sankyo Company, Limited has donated USD $1 million (approximately ¥115 million yen) to the United Nations Children's Fund (UNICEF).
In addition, Daiichi Sankyo Co., Ltd. matched 100% of the financial donations made by our employees in Japan and has donated a total of \22 million yen (approximately USD $180,000.)
Multiple Daiichi Sankyo group companies are likewise donating, by contributing to local charities and leveraging gift matching programs, adding to our overall support for those affected by this conflict. We are also thankful to our many employees who are helping privately, including hosting refugees in their homes.
We are working with our partners across the globe to ensure, as much as possible, that patients retain access to our medicines and our clinical trials worldwide.
We sincerely hope that this crisis will be resolved quickly and that peace in Ukraine and in neighbouring countries affected by the conflict will be restored soon.
The on-going tragedy in Ukraine is profoundly worrying, and our thoughts are with everyone impacted. Like many companies, we have team members in Ukraine, and we are committed to doing everything in our power to ensure their safety.
Protecting employees, serving patients
At the start of the Ukraine conflict, Ipsen convened a crisis committee with two key objectives: ensuring the safety of our employees and maintaining access to treatments for patients. At the time of this publication, all of our team members and their families in Ukraine are safe. And together with our partners, we are doing our very best to limit any impact to the supply of our medicines.
Humanitarian relief efforts
Beyond these two key priorities, we are also doing our part to provide humanitarian relief to the people of Ukraine via a donation of €1.5 million, split between two humanitarian organizations.
- Tulipe collects donations from health companies to respond to the emergency needs of populations in distress during acute health crises, natural disasters and conflicts via its partners in the field.
- The International Red Cross in France an independent charity working alongside governments and public authorities which undertakes neutral and impartial humanitarian action.
In addition, we have donated medicines and supported nearly 100 patients with three months’ of supply of their necessary treatment including 30 children with central precocious puberty.
Ipsen in Russia
As a pharmaceutical company, we have a responsibility to maintain patient access to our treatments. In line with our relentless commitment to serving patients, we will continue to tackle their healthcare needs regardless of their race, sex, nationality, ethnicity, country of origin, language, or religion.
We support global sanctions, and we will take all precautionary measures to comply with them. We have suspended several promotional activities in Russia, including advertising and participation to non-scientific congresses. Additionally, we will not initiate any new clinical trials.
As we continue to hope for a peaceful resolution of this conflict, our thoughts and solidarity are with everyone affected by this tragedy.
As a global healthcare company, Johnson & Johnson believes access to healthcare is fundamental. One year following the start of the war in Ukraine, we remain committed to our employees, their families, and the people of Ukraine. We have:
- Provided employees with a range of support including, security and immigration advice; financial assistance; resettlement and redeployment support; and assistance with mental health and well-being.
- Donated $10 million to support humanitarian assistance work and continuing to honor non-profit partner product requests in support of the crisis, as well as local fundraising efforts.
- Supplied our medicines and medical devices in the region.
- Suspended the supply of our personal care products in Russia.
- Suspended additional investment in Russia.
- Suspended all advertising in Russia.
- Suspended enrollment of clinical trials in Russia.
We will continue to monitor the need for humanitarian relief in the region and provide support to people impacted by the war.
Almirall stands in solidarity with everyone who is suffering first-hand the consequences of the conflict and humanitarian crisis in Ukraine.
As a company we are also committed to helping the humanitarian relief efforts and we have launched the giving campaign “Together with Ukraine” that has matched employee donations globally. All funds raised have been donated to the Spanish Red Cross (Cruz Roja Española), who is supporting the Ukrainian Red Cross response as well as regional Red Cross efforts in neighbouring countries.
Almirall has also accelerated donations of relevant medicines to NGOs operating in Ukraine and bordering countries. We have offered a total of more than 150,000 units of relevant medicines.
As a global biopharmaceutical company, we uphold respect for fundamental human rights around the world as part of our purpose to improve people’s lives.
Our thoughts are with the people of Ukraine, and we hope for a swift and peaceful resolution to the situation.
Our priority is on the safety of Astellas Ukraine employees and their families. Also, we are ensuring on-going partnership and connectivity with suppliers, distributors and key stakeholders to do our best efforts for continuous supply for patients.
We have taken steps to support the people in Ukraine. We are donating 10 million yen to UNICEF to support their humanitarian effort. We are also looking at other philanthropic options including essential drug donation and fund raising.
At Astellas, we are at the forefront of healthcare change to turn innovative science into VALUE for patients. We remain committed to our mission in all the countries where we operate.
Several months have passed since Russia’s invasion of Ukraine. From the outset, we have utterly condemned this brutal aggression against a sovereign country. Our hearts ache as we see the devastation and death affecting innocent civilians, including children. We stand by the people of Ukraine who can fully count on our solidarity and support.
Attacks like these demand a very clear stance. And we have been very clear about ours. Here is what we are doing:
Supporting the people and rebuilding plans in Ukraine
Bayer is fully committed to Ukraine´s future through investing in the country and supporting President Zelensky’s rebuilding plan – called United24. We aim to continue making significant investments in the country over the next decade – mainly to rebuild Ukraine´s agricultural system. This will also positively impact global food security, by enabling Ukraine´s farmers to plant and harvest their produce.
As a start, to cover the corn seed demand in Ukraine and beyond, Bayer will invest more than 30 million Euros from 2022 onwards in the Pochuiky seed plant. This investment includes raising the capacity of our seeds dryer, extra field equipment, additional storage facilities – and new employment opportunities in the region.
Further, Bayer supports the humanitarian non-profit organization “Fondation suisse de déminage” (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A donation of 825,000 euros will be dedicated to purchasing a large-size mechanical mine clearance machine. The machine is able to process large areas of land such as farmland and will allow farmers to grow food safely.
Bayer also continues to support Ukraine in the areas of health, education and humanitarian relief. We have donated a total of over 10 million Euros so far. This includes establishing a disaster relief fund and product donations, including antibiotics and oncology therapeutics. We will also support the rebuilding of Ukraine´s hospital and public health infrastructure.
As part of these efforts, we have donated 1.3 million euros to the UNITED24 fundraising platform. The donated amount will support two projects. Bayer will provide financial aid to restore the infrastructure of the Chernihiv Medical Center of Modern Oncology. We will also help the Romodanov Institute of Neurosurgery to purchase medical equipment for high-tech neurosurgical interventions and support complete patient rehabilitation.
Our employees donated more than 1 Million Euro through a Red Cross relief campaign, which Bayer has matched. The matching supports the procurement of several ambulances and defibrillators for Ukraine and the set-up of a mobile medical aid center serving Ukrainian refugees in Poland.
In addition to the seeds and agricultural inputs that the team in Ukraine supplied and continues to supply to farmers, Bayer has donated more than 40,000 bags of seeds to grow food on nearly 30,000 hectares. The seeds will support 1,250 small farmers in Ukraine who had difficulty in accessing input for the 2022 growing season.
We continue to prioritize the safety of our 700 colleagues in Ukraine and will continue to support them.
Furthermore, Bayer country organizations and employee-led initiatives have organized local volunteering campaigns. One example is the commitment of the team from Bayer Gastronomy, which converted the "Seminar- & Tagungshotel Große Ledder" training center in Wermelskirchen near the Bayer headquarters in Leverkusen into a shelter. 30 Ukrainians find a temporary home there. Bayer volunteers are supporting the refugees and assist them in administrative issues.
Stopping all non-essential business in Russia and Belarus, while ensuring continued access to health and agriculture products
As a direct response to Russia’s invasion of Ukraine in February, Bayer stopped all spending in Russia and Belarus that is not related to supplying essential products in health and agriculture. This means we have stopped
- Delivering non-essential products
- All advertising and other promotional activities
- Capital investments indefinitely
- Pursuing any new business opportunities in those countries.
We have also heard voices calling for a complete stop of delivery of all our products to Russia and Belarus. We understand these concerns as the war raises moral and ethical issues for every company.
Our position is clear – this war, initiated by Russia, is taking too many lives every day. As a Life Science company, we have an ethical obligation – in every country we operate in. Withholding essential healthcare and agriculture products from the civilian populations – like cancer or cardiovascular treatments, health products for pregnant women and children as well as seeds to grow food – would only multiply the war’s ongoing toll on human life.
Bayer is fully committed to helping prevent what could become an unprecedented food crisis. We share the view of the UN that global access to Ukraine’s food products and Russian food and fertilizers is essential to alleviate pressure on the global food system. In line with this, we have decided to continue supplying Russian farmers with essential agricultural products to ensure they can contribute to fulfilling the global demand. At the same time, we hope the Russian government continues to safeguard the free flow of agricultural products and never again use food as a means of pressuring the world.
Through our commitments, we act in the spirit of the UN, the G7 and the European Union calling for ensuring global food supply and access to healthcare.
These are difficult times that put us to the test, both, emotionally and ethically. At Bayer, we do everything in our power to live up to our responsibility to reduce the suffering caused by this terrible war. This is what our vision “Health for all, Hunger for none” calls for.
The situation remains volatile, and we will continue to monitor developments and evolve or adjust our response as necessary. As we do so, we stand with all those calling for an immediate end to this war, and we hope and pray for peace to return to Ukraine – and our world.
Biogen is heartbroken by the war in Ukraine and stands firmly with the global community in providing humanitarian aid. Consistent with our values, the Biogen Foundation launched an employee giving campaign that is doubling employee donations. Together we have already raised a total of more than $550,000 and counting, to provide medical supplies, food, water and other essential support through five charitable organisations: the International Medical Corps, Polish Humanitarian Action, the Swiss Red Cross, UNICEF and UNHCR. In addition, the Biogen Foundation is supporting the Swiss Red Cross and Poland Humanitarian with grants totalling $250,000.
We are also working closely with patients, the medical community and governments to ensure people living with spinal muscular atrophy (SMA) displaced by the war in Ukraine have access to treatment across Europe. To that end, Biogen and the Biogen Foundation have provided a €25,000 grant to SMA Europe and are in communication with our partners to guarantee continued patient care.
This assistance is part of an overall commitment of $1.5 million that also includes Biogen in-kind contributions of essential supplies, employee relief bonuses and volunteering.
Bristol Myers Squibb and the Bristol Myers Squibb Foundation are each actively contributing to relief efforts in Ukraine, donating more than $1 million total to date.
The Company has provided donations to a number of organizations coordinating relief efforts; this includes activities organized by the World Institute on Disability and the ECO-ASCO special network, working with WHO Europe to pool information to aid the coordination of transfer and care for Ukrainian cancer patients.
The Bristol Myers Squibb Foundation has provided donations to organizations, including Americares, Direct Relief, International Rescue Committee, and Save the Children.
The Foundation is also matching contributions by our employees globally to organizations providing relief to Ukraine.
Aligned with Our Promise to protect human health, CSL is supporting multiple humanitarian relief efforts in the region. We are working with aid organizations, including the World Health Organization (WHO), the European Health Emergency preparedness and Response Authority (HERA), the EU Civil Protection Mechanism and the Red Cross to provide our life-saving medicines to those impacted by the invasion. We have also been coordinating our local relief efforts with international organizations, including Doctors Without Borders and UNICEF.
By providing our medicines through humanitarian, intergovernmental and EU-coordinated efforts, we will help refugees and those who remain in Ukraine access essential therapies.
In addition to providing our life-saving medicines, CSL has pledged to match monetary donations from our eligible employees around the world to support urgent relief efforts, including a program that enables eligible employees to donate plasma at CSL Plasma collection centers and then direct the payment to the Red Cross.
Together, our product and monetary contributions will continue to support relief efforts both within Ukraine and in neighboring countries.
While we continue to keep the Ukrainian people, and those in the surrounding regions, in our thoughts as we hope for a peaceful resolution, we also understand there are many people in Russia who rely on our life-saving therapies. CSL will continue to support those living with rare and serious diseases in Russia and supply products which are critical for patients. As the invasion persists, CSL will not conduct any promotional activities and will not start new clinical trials in Russia until further notice.
Under its hhc philosophy to increase the benefits that medicines bring to patients and their families, the Eisai Group, as an international pharmaceutical company, strives to contribute to the health and well-being of all people, wherever they may be.
To further this mission, we are working with various partners including the International League Against Epilepsy to make our medicines available to those patients who have been displaced by the war in Ukraine and who are in desperate need of medication. In addition, as humanitarian support to those who have been severely affected in Ukraine and those who have been evacuated to the surrounding countries, the Eisai Group has donated approximately 16 million yen to the Japanese Red Cross Society, the international non-governmental organization Association for Aid and Relief (AAR), Japan and other organizations.
Alongside the global community, we share deep concern about the tragic events happening in Ukraine. We are taking actions guided by our purpose, and as a company dedicated to health and care for people and patients.
Our first priority is the safety, security and wellbeing of GSK people, wherever they are located. After this, our focus is to make sure our products reach the people who need them, including supporting humanitarian efforts in Ukraine and surrounding countries.
We condemn the fighting and the harm and suffering it’s causing to people in Ukraine and beyond. The actions taking place are in violent contradiction to our purpose, and unshakeable belief that all people should be treated with dignity, respect and humanity.
For full information on GSK’s humanitarian support and GSK in Russia, please visit GSK.com [Our response to the situation in Ukraine | GSK].
Supply of medicines to people in Ukraine
In early March, Lilly announced it is donating $7.5 million of insulin to Project Hope, a U.S. non-profit organization that empowers health care workers facing the world’s greatest health crises to build resilient communities and a healthier, more equitable world. Project Hope is currently on the ground in Ukraine and is actively shipping essential medicines and medical supplies to assist Ukrainians.
To date, Lilly’s supply of medicines, including more than two million doses of diabetes and cancer products, have made their way to hospitals and patients in Ukraine via our humanitarian partners. The most significant supply of medicines includes insulins with more than 117,000 vials and pens delivered thanks to Direct Relief and Project HOPE.
A supply of Lilly’s COVID-19 therapies is in route to Ukraine and two additional supplies of diabetes and cancer products are in process with Direct Relief. Lilly continues to monitor the situation and to do what we can to contribute to the health and wellbeing of people in Ukraine during this ongoing and devastating crisis.
More information is available here Lilly Ukraine Support | Eli Lilly and Company
The Lilly Foundation has made two equal monetary contributions totalling $500,000 to Direct Relief and to Americares to support their respective relief efforts in the region. Americares is currently working to deliver aid for families facing crisis in Ukraine. They are collaborating closely with the World Health Organization, regional health authorities, and international, national and local response organizations in Ukraine and neighbouring countries.
The Lilly Foundation will also match eligible Lilly employee donations up to an additional $500,000. We hope for an immediate end to the hostilities and a peaceful resolution to this crisis as soon as possible.
Lilly Shifts Business Focus in Russia
For nearly 150 years, Lilly has worked to ensure patients have access to the medicines they need, no matter where they may live. We have an ethical and moral obligation to help alleviate human suffering and to protect the lives of patients. Lilly is deeply concerned with the tragic loss of innocent lives in Ukraine – and recognizes the challenges people are facing with access to essential medications like insulin.
We have taken several actions in response to the crisis in Ukraine. In addition to our donations of lifesaving medicine and the Lilly Foundation’s philanthropic commitment announced on March 3, Lilly has been focused on the safety of our employees in Ukraine.
We also have suspended all investments, promotional activities, and new clinical trials in Russia, as well as the exportation of non-essential medicines to that country. Our Russian operations are now only focused on ensuring people suffering from diseases like cancer and diabetes continue to get the Lilly medicines they need. Should we generate any profits from our sales in Russia, we will donate them to organizations dedicated to humanitarian relief.
We hope for an immediate end to the hostilities and a resolution to this crisis as soon as possible.
*The Eli Lilly and Company Foundation, Inc. is a separate, tax-exempt organization.
The French pharmaceutical industries support the Ukrainian population by sending medical products on territories at war through their association Tulipe.
Thanks to the donation of the volunteer French pharmaceutical firms, the association managed to route to Ukraine and Poland more than 100 tons of medical products (war medicine material and general medical products for refugees) since the beginning of the armed conflict. These donations are organized in coordination with the Crisis and Support Center (CDCS) of the Ministry for Europe and Foreign Affairs and various NGOs.
As the conflict continues, more donations are on the way for the coming days and weeks, in partnership with humanitarian organizations located in the field. (October 2022)
LEO Pharma stands united with the people of Ukraine and with the international community in condemning the invasion.
As of March 22nd 2022, LEO Pharma has decided to donate close to 740,000 packs and 420,000 vials of antibiotics and anticoagulants via International Health Partners. These medicines are relevant for treating wounds, infections and saving lives to support people in vulnerable communities in Ukraine.
The products have an estimated value of EUR +1.8 million and is a donation on top of the DKK 1 million (EUR 135,000) donated to the Danish Red Cross.
- To support humanitarian aid in Ukraine, Merck has in total donated more than 4 million euros. More than half a million euros came from our colleagues from all around the world. The majority was donated to the German Red Cross.
- Two trucks delivered more than 40 tons of relief supplies in form of food, first-aid equipment, hygiene articles and other urgently needed daily necessities from Merck in Darmstadt to Wroclaw in Poland to support refugees there. Here, too, our employees made a big contribution through their donations.
- In June, Merck donated a six-month supply of its medicines for the treatment of thyroid disorders and for the treatment of colorectal cancer and head & neck cancer to Ukraine.
- More than 160,000 euros were collected in cash and in-kind donations from European subsidiaries, including drug donations of several medicines.
- Merck also donated more than 20,000 liters of disinfectant.
- To help those displaced by the war, we offer dedicated areas of opportunity in Germany on our “Helping Hands for Ukraine” career page.
Novartis continues to condemn the ongoing conflict in Ukraine, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
As a medicines company, Novartis has delivered more than 1.5 million packs of medicines—which amounts to approximately USD 38 million in medical aid—to maintain the supply to those who rely on these drugs in Ukraine and the border areas where people are seeking refuge. This is in addition to an initial USD 3 million donation to charities supporting refugees and displaced people in Ukraine and bordering countries. Our associates, in solidarity, have voluntarily donated USD 2.2 million.
Patient organizations (POs) face an unprecedented challenge to deliver their core support services and address other pressing needs during this war. This includes services such as patient transfer to get treatment abroad, translations of medical reports and patient data, and dissemination of knowledge of hospitals prepared to admit patients, among others. POs are rising to the challenge to ensure the health and safety of their constituents, which Novartis is supporting with a USD 1 million aid.
The safety and security of our people remain our top priority, and we will constantly review the situation in the country. With the start of aggression, we suspended our operations in Ukraine and focused on humanitarian support. Our team in Ukraine is now working remotely and continues to play a critical role in maintaining our priority to ensure that those in need of life-changing medicines receive the best possible support from Novartis and Sandoz.
For more information on Novartis support, please visit Novartis.com [News | Novartis].
As the humanitarian crisis deepens in Ukraine, all at Otsuka watch with great sadness and a feeling of helplessness. The impact on the people in Ukraine and those fleeing their homes is unimaginable and we hope that our donation of €100,000 to the British Red Cross will contribute to providing a degree of safety and security to those affected by this humanitarian crisis. We continue to monitor the situation and respond with support where we can.
We are working diligently to support the country and people of Ukraine with medical products in accordance with Roche’s overall mission. As a first initiative, we donated a critical antibiotic and specialised medicines for the treatment of anaemia, a wide variety of bacterial infections, influenza, rheumatoid arthritis, SMA and various cancers as well as rheumatoid arthritis and COVID-19. We also donated reagents and consumables for automatic testing of blood donations and units for diabetes management.
We remain in contact with multiple global and local partners as well as charities to understand how it can best continue to support the people of Ukraine with additional medical supplies.
Ensuring critical medicines and diagnostics reach the people who need them is extremely important to us and we are making every effort to ensure continued supply within the scope of the available possibilities.
We are working with local distributors in Ukraine, and have set up a remote support system for laboratories, through our Diagnostics Customer Support Center in Poland.
We have established a global hotline number and invite patients, caregivers, physicians, clinical trial participants, investigators or coordinators, and healthcare providers to call. Our team will do its best to provide everyone who is in need with the appropriate information and support. The hotline is available in multilingual and can be reached on the following number: +36 146 182 58.
The situation is evolving quickly and further details will be shared when available.
Find more information about our donations here:
- We are offering support to our employees in Ukraine and to those who have made the difficult decision to leave the country. Many Servier employees are working to ensure the safety and well-being of their Ukrainian colleagues and their families in any way possible, including offering solutions for housing.
- We are doing everything we can to contribute to humanitarian aid intended for the Ukrainian population. The Servier Group has already made donations of medicines and emergency kits, and has made financial donations, for a total amount that exceeds €13.5 million to date.
- We have also created a fund for our employees around the world so that they may contribute to relieving suffering in Ukraine via voluntary charitable donations. Servier matches all employee donations by applying the 1:1 rule whereby 1 euro given by an employee = 1 euro paid by the Group.
Our commitment to patients, regardless of where they live, and to our people is unwavering and is even more important in times of crisis. We are making every effort to protect our colleagues in Ukraine and to continue to supply patients in Ukraine and in the region with much needed treatments.
We are supporting the global humanitarian efforts by contributing JPY 300 million (approx. $2.6 million USD) to The International Federation of Red Cross and Red Crescent Societies, which is actively providing urgent local humanitarian support to people displaced and impacted by the conflict. We are also donating medicines to hospitals working to provide care around the clock to patients in need, and will continue to evaluate ways to provide additional support services for patients and the treatment community. Our colleagues around the world are helping those in need in Ukraine by contributing with their personal donations to several local and global non-governmental organizations.
As the conflict and humanitarian crisis in Ukraine continues, we are announcing an update to our company position in Russia.
Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to our employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrollment of new patients in ongoing clinical trials.
Our focus only on essential activities is consistent with our values and ethical responsibility to our patients in Ukraine, Russia and the region who depend on our treatments. Notwithstanding, we are adhering to all international sanctions imposed on Russia.
We will be increasing our humanitarian relief efforts, including monetary and medicine donations to benefit people affected by the conflict in Ukraine, and we will continue to assess new ways to provide support as we look to meet the needs of patients across the region.
Takeda will continue to monitor the situation closely and take appropriate actions grounded in our values.
In these difficult times, UCB is guided by our purpose of creating value for patients, now and in the future and our focus on contributing to a more inclusive and sustainable world. That’s why we are driven to limit the impact of this unfortunate war on our employees, patients and their respective communities.
We are fully focused on supporting the small group of UCB employees living in Ukraine, as well as their families, and we have foreseen emergency support for our colleagues.
We feel responsible to bring medicines to people living in Ukraine and Russia no matter how difficult the circumstances. We will do everything within our power to ensure patients have access to their medicines. This is extremely difficult because of disrupted supply chains. In spite of this, we continue to investigate short and longer-term solutions to ensure availability of our medicines in the region. We have a cooperation with NGOs such as Tulipe who are delivering drug donations to patients in the war zone. So far, we have donated more than 1,6 million doses of anti-epileptics and 35,000 daily doses of antihistamines.
To support humanitarian efforts, UCB has donated EUR 300,000 to the German International Rescue Committee and the Belgian International Red Cross. We are also examining how we can support the communities in the region and those who have fled to safer places in the long-term, through our UCB Community Health Fund.
UCB is also supporting BEforUkraine, a Belgian non-profit organization, in bringing essential equipment to Ukraine: the company has so far financed 3 refurbished ambulances filled with equipment.
UCB colleagues around the world are showing solidarity, helping in refugee centers, making personal donations to charities, setting up collection of essential goods at UCB sites, driving to the Ukrainian border to pick up relatives or friends and hosting Ukrainian colleagues and refugees in their houses or those of other colleagues. These are only a few examples. To facilitate this much-needed movement of solidarity, we have developed an employee volunteering initiative to enable our colleagues in Europe to lend a helping hand to this enormous refugee crisis.
UCB in Russia
UCB is still bringing medicines to patients in Russia but we have reviewed the way in which we conduct our business there. Profits generated in Russia will be donated to NGOs to help the people of Ukraine. We have already stopped enrolling new patients and are not starting up any new sites or clinical trials in Russia. We are no longer undertaking marketing activities and are exploring other steps we can take to support the sanctions.
Throughout the past weeks of conflict in Ukraine, Gilead’s focus has been on safeguarding our employees in the region and ensuring that people who rely on our medicines are able to receive them. Gilead has a long-standing presence in Eastern Europe and Central Asia (EECA). Working with many partner organizations, we provide treatments and support to help people in the region with various diseases and conditions, predominantly HIV, hepatitis and COVID-19. We are now doing everything possible to ensure that this work continues. In a war where too many innocent people are suffering, we feel strongly that no individual should go without medicine that might save their life.
Our teams are working alongside distribution partners as well as humanitarian and non-governmental organizations to get our treatments to people who need them. Ukraine bears the second-highest number of HIV cases in EECA, according to UNAIDS. We are working with others to address the needs of Ukrainian refugees with HIV who are now in neighboring countries including Poland, Moldova, Czech Republic, Romania and Russia.
Beyond the provision of medicines, Gilead supports multiple partner and grantee organizations in the region that are dedicated to removing societal barriers to care. This includes our RADIAN program, for example, which works to raise awareness about HIV, reduce stigma and link people to testing and care. None of us wants to see any setback in progress for this critical work because of the war. Gilead is in ongoing contact with the various community-based organizations we support to see what additional resources or help they might need. To support the broader humanitarian efforts in Ukraine, the Gilead Foundation has donated $3 million USD and in addition, a matching-donation program for Gilead employees has raised $700,000 to date.
While we remain committed to facilitating patient access to our life-saving medicines in Russia, all non-essential business operations in the country have been suspended. Any profits made from the sale of medicines will be donated to the humanitarian efforts for Ukraine. The initiation of new clinical trial sites in Russia and Ukraine has been paused, and we are working with local trial investigators to see how we can best manage existing trial sites in affected areas. Again, we are fully committed to mitigating any impact on any patient, regardless of what country they are in.
It is shocking that we find ourselves witnessing these tragic repercussions of war, with so many people at risk, not just from the fighting itself but from the many implications of the conflict. We are committed to doing everything in our power to help while also fulfilling our existing responsibilities in the region. Ultimately, we are a company whose purpose is to help people live healthier lives and we will do everything possible to fulfill that purpose, working with others who share our aim.
Our priority has been and will continue to be to take care of our colleagues and patients both in Ukraine and Russia that are innocent people in the midst of war.
MSD has a more than 130-year legacy of saving and improving lives around the world, and we remain committed to doing so. We are saddened by the invasion of Ukraine and stand united with the Ukrainian people who face a humanitarian crisis. MSD’s hope is for an urgent resolution, and our paramount concerns are the safety and well-being of our employees and ensuring our patients and customers have continued access to our medicines and vaccines.
For humanitarian reasons, MSD has a responsibility to continue supplying essential medicines and vaccines in Russia. Any profits resulting from these sales will be donated to humanitarian causes. We will maintain scientific exchange of information with stakeholders in critical therapeutic areas. However, the company will not make further investments in Russia. This includes stopping all promotional activities, capital investments and business development initiatives. Additionally, screening and enrollment in ongoing clinical trials, and planning for new studies in Russia have been suspended. We are continuing to treat patients already enrolled in existing clinical trials and collect data from these studies underway, and we are working hard to ensure no patient is left behind. MSD does not have research or manufacturing facilities in Russia and is operating in compliance with all international sanctions while working to ensure continued access to essential medicines and vaccines. During this time of tragedy, MSD’s commitment to helping the people affected is unwavering. We are using our resources to help alleviate the human suffering in Ukraine. Merck and Co., Inc. and MSD are taking various actions to address the humanitarian crisis in Ukraine, which include the:
- Delivery of 135,000 courses of molnupiravir to the country through a supply and purchase agreement we have with the government.
- Donation of 100,000 courses of molnupiravir to Direct Relief, an organization that provides emergency medical assistance for distribution to refugees in low- and middle-income countries including people affected by the conflict in Ukraine. We are utilizing our global network, including 17 internal and external manufacturing sites in nine countries, which don’t include Ukraine or Russia.
- Commitment of $1 million USD to NGOs, including $300,000 USD to the American Red Cross, delivering urgent assistance to those affected in the region.
- Utilization of our donation program for U.S. and Puerto Rico employees to donate to Ukraine relief efforts. Contributions will be matched 100% by the Company. Employees outside of the U.S. can receive a company match toward their donation to the Red Cross and to Direct Relief, and the contribution will be matched 100% by the company.
- Donation of vaccines from MSD Animal Health to farmers in Ukraine to support the continued raising of livestock and food production.
Additionally, we are continuing to explore ways, in discussion with NGOs and relief experts, to use our resources to alleviate the human suffering in Ukraine.
As of April 13, our total cash and product donations amount to more than $95 million USD.
MSD will continue to monitor this tragedy and update its response as this crisis unfolds. The focus now remains on supporting the well-being of our employees and doing what we can to ensure access to our medicines and vaccines, and further using our resources to alleviate the unimaginable human suffering in Ukraine.
Novo Nordisk is deeply concerned by Russia’s invasion of Ukraine, and our thoughts are with all those affected by this unfolding human tragedy.
As a healthcare company striving to improve the health and wellbeing of people across the globe, we strongly condemn all acts of violence and aggression, and stand with all those calling for a swift and peaceful resolution to this war.
Since the invasion started, we have been doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine and to those fleeing – both by prioritising supplies through the regular reimbursement system still operating in most of the country and through humanitarian donations of diabetes and haemophilia care products. Novo Nordisk has been coordinating closely with a range of national and international actors – including the Ministry of Health and humanitarian actors. Several months of supplies have been donated to Ukraine and neighbouring countries - responding to requests for donations from the Ministry, hospitals, patient organisations and international actors, including Direct Relief, WHO and the ICRC.
As of May 25th, we have reopened our office in Kyiv as the situation in the Ukrainian capital stabilises. The reopening is on a voluntary basis for employees and we are continuously reviewing the situation to ensure their safety.
Our products remain available in approximately 80% of Ukraine. For healthcare professionals and patients, we continue to support questions about product availability through our dedicated hotline:
0-800-801-341 Toll-Free number in Ukraine
032-246-50-73 Number in Ukraine (charges according to local operator)
+48-22-4444911 International number
The Novo Nordisk Foundation has donated 80 million Danish kroner (approx 10.7m Euro) to support the work of international relief organisations in receiving and assisting refugees, internally displaced people and other vulnerable groups with access to basic necessities such as food and shelter, health and protection.
Pfizer stands with the unified global community across the public, private, and civil society sectors in opposition to the Russian war in Ukraine and the situation it has created. Deeply concerned by the human suffering we all are witnessing during the ongoing war in Ukraine, Pfizer is committed to contributing to ongoing humanitarian efforts that support the safety, health, and wellbeing of people affected by these tragic events. Consistent with our company values, Pfizer is determined to ensure the safety of our colleagues and their families. We are equally determined to facilitate continued access to our medicines and vaccines for patients. Pfizer is donating the equivalent of all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.
To date, we have activated several humanitarian efforts and continue to expand our support, mostly through The Pfizer Foundation , a charitable organization founded by Pfizer Inc to address the challenges of a complex and evolving global health landscape.
Supporting global and local NGOs
To date, more than $22 million has been donated through The Pfizer Foundation to causes supporting the Ukrainian people. This includes grants derived from Pfizer’s decision to donate the equivalent of profits from our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.
To date the Foundation has approved grants for 12 non-governmental organizations (NGOs), including six local organizations in Poland and Ukraine to support humanitarian relief and response efforts. This includes food security and support services, shelter, education for children, and other pressing needs of the people of Ukraine.
Our humanitarian relief partners:
- Crown Agents International Development, Ukraine
- International Medical Corps
- International Rescue Committee
- Polish Center for International Aid Foundation
- Polish Humanitarian Action
- Polish-Ukrainian Institute for Relief and Development
- Save the Children Ukraine Emergency Response
- Ukrainian Red Cross
- UNICEF Ukraine Emergency Response Fund
- UNITED 24
- World Food Program Ukraine Emergency Fund
Collectively, these partners are on the front lines supporting emergency relief priorities in Ukraine and the immediate needs of displaced populations in surrounding countries now hosting Ukrainian refugees. Their work includes repairing vital infrastructure in Ukraine, restoring and equipping health facilities, and supporting displaced populations to address critical needs including food security and support services, child protection and education, and safe shelter.
Maximising the generosity of Pfizer colleagues
Through The Pfizer Foundation, we have also launched the Ukraine Humanitarian Disaster Campaign matching financial donations already made by thousands of Pfizer colleagues around the world to UNICEF, the IRC, Save the Children, the American Red Cross, CARE, Nova Ukraine, and Sunflower of Peace.
- As of August 2022, more than 4,300 colleagues from nearly 54 countries have donated nearly US $936,000
- Including The Pfizer Foundation’s dollar-for-dollar match, the total donation is US $1.86 million
Providing our medicines and vaccines to those that need them
Pfizer is also responding to the immediate need for access to life-saving medicines through targeted product donations to Ukraine and organisations supporting the Ukrainian people. This includes over 1,000,000 doses/courses of Pfizer products, including lifesaving antibiotics, antifibrinolytics and oncology medicines to help healthcare providers and relief workers treat patients in Ukraine and neighboring countries.
In partnership with the U.S. Government and USAID, almost 2 million donated doses of the Pfizer/BioNTech COVID-19 vaccine have also reached Ukraine.
We are also one of the largest donors to Direct Relief. As part of a broader product donation, we have delivered nearly 200,000 courses of PAXLOVID to Ukraine.
*The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions
Pfizer has a cross-functional team of people dedicated to ensuring the safety of our colleagues and contractors based in Ukraine. We remain in close contact during this extremely challenging time, and we continue to provide advice and support. At this time, all colleagues have been accounted for and we remain in almost constant contact during this extremely challenging time.
We are working hard to facilitate patients’ access to the medicines and vaccines they need. We have established robust and preventative measures as well as flexible routes to help minimize impact on supply to Ukraine. We also continue to manage stock levels of critical medicines to ensure we can serve patients in the country.
At the same time, we are continuing our collaboration with research partners in the region to mitigate impact to our clinical programs. In the interests of patient safety, we made the necessary decision to pause the recruitment of new participants to clinical trial programs on the outbreak of conflict, and we have focused on maintaining continuity of care for patients actively participating in trials.
We are actively working with all our clinical trial sites in Ukraine to support them however possible in continuing to support patients and advance medical science. We are truly amazed at the resilience of the Ukrainian trial sites, healthcare professionals, patients, and all those involved—many of whom have continued on their clinical trials as planned despite the challenging situation.
We are also working with the appropriate channels in the surrounding countries to connect with any displaced participants to facilitate their enrolment onto trial sites in their chosen location.
We will continue to evaluate the situation and adjust our approach as needed
We continue to be shocked and saddened by the brutality of the Russian armed forces against Ukraine and the resulting suffering of the Ukrainian people. The enormity of this tragedy demands a sustained response. We stand with the international community in opposing the Russian war and actively supporting the people of Ukraine.
Since the beginning of the war, we have relentlessly worked to provide the Ukrainian people the access to our treatments and vaccines and to mitigate the impact of the situation on our ongoing clinical trials in the country. We have been working hand in hand with the healthcare authorities and our partners at Foundation S - The Sanofi Collective, accelerating the donation of our essential medicines and vaccines and supporting both patients in Ukraine and Ukrainian refugees in neighboring countries. The whole donation amounts to 31M€, representing almost one donation per week since the beginning of the tragedy.
Through Foundation S, we have donated EUR 5 million to the Red Cross (and ICRC) for Ukraine and neighboring countries and to UNHCR, the UN Refugee Agency. This has supported emergency access to necessities such as food, shelter, medicine, and security, and helps receive and assist refugees from Ukraine. In addition, as of today, we have donated 37 Million daily treatments covering various diseases for the Ukrainian people, equivalent of 21 Million patients treated, half of the total Ukraine population. Moreover, as part of our effort to support the European Commission’s ‘Stand Up For Ukraine' donation campaign, we have donated 450,000 vaccines to support diphtheria, tetanus, and flu vaccinations for the Ukrainian people.
Further to Foundation S’ donations, employee donations have also been organized across our country affiliates, with 2,800 employees’ participation leading to 690,000 euros collected in a matching fund.
Our support effort goes beyond donations. We are working with local partners to re-establish sustainable supply channels to distribute our medicines and vaccines in Ukraine. We strongly believe that we can make a key contribution for a sustainable response to the crisis by restoring the infrastructures that secure supply our medicines and vaccines in the country.
We will continue our effort to respond as the situation evolves.
Teva has shipped over 1.3 million packs of medicines, including antibiotics and other medicines listed on the WHO's list of essential medicines, as well as products for Ukrainian infants and children struggling with poor hygienic conditions.
If you want to learn more the full release is available here: https://bit.ly/3i4llGS
In light of the developing humanitarian crisis in Ukraine, our thoughts are with everyone affected - and in particular our patients, employees and their loved ones.
At Vifor Pharma, we are working hard to strengthen wider humanitarian efforts and have donated nearly 60,000 packages of iron therapies to help those in need in Ukraine. The use of the intravenous iron products in this emergency setting is hoped to improve surgical and medical outcomes in patients by optimal management of a patient’s additional transfusion needs during surgery as evidenced in the Patient Blood Management setting.
Vifor Pharma is a patient-centric company, and our greatest priority is to ensure that local healthcare organizations and patients receive the medicines they depend on in these uncertain times.